Cold chain logistics: 3 myths emerging biopharma must overcome

For emerging biopharma, managing cold chain logistics can feel like navigating a maze. With complex regulatory requirements, strict temperature controls and high stakes for product integrity, the logistics of getting temperature-sensitive therapies to market can seem daunting.

But cold chain logistics doesn’t have to be a challenge. By understanding the key myths and taking a strategic approach, smaller pharma companies can build a reliable and scalable distribution strategy, without unnecessary complexity or excessive costs.

Myth #1: You should leave cold chain logistics to others

Cold chain logistics is essential for any company handling temperature-sensitive medicines, but it can sometimes be seen as too complex or specialised for smaller organisations. This assumption may mean companies avoid exploring advanced solutions, deferring key decisions to logistics providers or relying on fragmented solutions that seem cost-effective at first, but introduce risks later down the line.

Taking a more active role in understanding the options and engaging with cold chain solution providers can simplify decision making, improve risk management and ensure compliance. The key is finding solutions that align with the scale of operations, whether for clinical trial shipments, small-batch commercial launches, or scaling up to larger distribution networks.

Access to the right expertise and solutions will help smaller companies navigate regulatory requirements, reduce risk, and maintain product integrity without adding unnecessary complexity.

Myth 2:  All providers offer the same level of protection

It’s easy to assume that once a shipment is handed over to a logistics provider, temperature control and security are fully managed. While logistics partners play a critical role, smaller pharma companies may find themselves with limited visibility into their own shipments, making it harder to anticipate potential issues and respond quickly. Having access to shipment data and real-time monitoring gives companies greater control over their products in transit. Without this level of oversight, a failed shipment, delays, or mishandling, can have serious financial and reputational consequences.

A direct relationship with a dedicated cold chain expert provides the control needed to avoid costly setbacks, ensuring that smaller companies can manage risk more effectively and maintain product integrity.

Myth #3: Cold chain is only about temperature control

Selecting the right packaging goes beyond maintaining the correct temperature and humidity. It also impacts logistics efficiency, cost management, and regulatory compliance, which are critical factors in ensuring smooth and secure shipments. Some companies settle on the packaging choice without considering factors like availability of the required solution, transit duration, and environmental conditions.

For smaller companies, a well-chosen temperature-controlled solution can mean fewer disruptions, lower costs, and improved shipment reliability.

Mastering the cold chain
Cold chain logistics comes with its challenges, but with the right approach, it can become a competitive advantage. By addressing these three common misconceptions, selecting solutions that fit operational needs, and tapping into industry expertise, emerging biopharma companies can strengthen supply chains, reduce risk, and ensure safe and efficient delivery of their products.

Are you ready to learn more? Contact us